دورية أكاديمية

Exploring the association between erythema multiforme and HIV infection: some mechanisms and implications.

التفاصيل البيبلوغرافية
العنوان: Exploring the association between erythema multiforme and HIV infection: some mechanisms and implications.
المؤلفون: Manenzhe SC; Department of Periodontics and Oral Medicine, School of Dentistry, University of Pretoria, PO Box 1266, Pretoria, 0001, South Africa., Khammissa RAG; Department of Periodontics and Oral Medicine, School of Dentistry, University of Pretoria, PO Box 1266, Pretoria, 0001, South Africa. razia.khammissa@up.ac.za., Shangase SL; School of Dentistry, University of Pretoria, Pretoria, South Africa., Beetge MM; Department of Periodontics and Oral Medicine, School of Dentistry, University of Pretoria, PO Box 1266, Pretoria, 0001, South Africa.
المصدر: AIDS research and therapy [AIDS Res Ther] 2024 Apr 18; Vol. 21 (1), pp. 24. Date of Electronic Publication: 2024 Apr 18.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101237921 Publication Model: Electronic Cited Medium: Internet ISSN: 1742-6405 (Electronic) Linking ISSN: 17426405 NLM ISO Abbreviation: AIDS Res Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, 2004-
مواضيع طبية MeSH: HIV Infections*/complications , HIV Infections*/drug therapy , Erythema Multiforme*/diagnosis , Erythema Multiforme*/etiology , Opportunistic Infections*/complications, Humans ; Simplexvirus
مستخلص: Erythema multiforme (EM) is an immune-mediated mucocutaneous condition characterized by hypersensitivity reactions to antigenic stimuli from infectious agents and certain drugs. The most commonly implicated infectious agents associated with EM include herpes simplex virus (HSV) and Mycoplasma pneumoniae. Other infectious diseases reported to trigger EM include human immunodeficiency virus (HIV) infection and several opportunistic infections. However, studies focusing on EM and human immunodeficiency virus (HIV) infection are scarce. even though the incidence of EM among HIV-infected individuals have increased, the direct and indirect mechanisms that predispose HIV-infected individuals to EM are not well understood. In turn, this makes diagnosing and managing EM in HIV-infected individuals an overwhelming task. Individuals with HIV infection are prone to acquiring microorganisms known to trigger EM, such as HSV, Mycobacterium tuberculosis, Treponema pallidum, histoplasmosis, and many other infectious organisms. Although HIV is known to infect CD4 + T cells, it can also directly bind to the epithelial cells of the oral and genital mucosa, leading to a dysregulated response by CD8 + T cells against epithelial cells. HIV infection may also trigger EM directly when CD8 + T cells recognize viral particles on epithelial cells due to the hyperactivation of CD8 + T-cells. The hyperactivation of CD8 + T cells was similar to that observed in drug hypersensitivity reactions. Hence, the relationship between antiretroviral drugs and EM has been well established. This includes the administration of other drugs to HIV-infected individuals to manage opportunistic infections. Thus, multiple triggers may be present simultaneously in HIV-infected individuals. This article highlights the potential direct and indirect role that HIV infection may play in the development of EM and the clinical dilemma that arises in the management of HIV-infected patients with this condition. These patients may require additional medications to manage opportunistic infections, many of which can also trigger hypersensitivity reactions leading to EM.
(© 2024. The Author(s).)
References: J Int AIDS Soc. 2016 Mar 03;19(1):20697. (PMID: 26945343)
J Immunol. 2014 Feb 15;192(4):1732-44. (PMID: 24446519)
J Antimicrob Chemother. 2008 Nov;62(5):879-88. (PMID: 18653488)
J Immunol. 2004 Aug 15;173(4):2410-8. (PMID: 15294954)
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Dec;120(6):707-16. (PMID: 26455287)
J Clin Aesthet Dermatol. 2009 Mar;2(3):51-5. (PMID: 20729944)
Front Immunol. 2023 Jul 11;14:1203531. (PMID: 37497218)
Med J Aust. 2015 Mar 16;202(5):273-5. (PMID: 25758702)
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):270-8. (PMID: 22614900)
Int J Dermatol. 2012 Aug;51(8):889-902. (PMID: 22788803)
Int J STD AIDS. 1992 Jan-Feb;3(1):56-7. (PMID: 1543771)
J Clin Diagn Res. 2014 Sep;8(9):ZH01-4. (PMID: 25386550)
J Infect Dis. 2015 Jun 1;211(11):1726-34. (PMID: 25489001)
PLoS Pathog. 2014 May 15;10(5):e1004078. (PMID: 24831517)
Clin Rev Allergy Immunol. 2018 Feb;54(1):177-184. (PMID: 29352387)
J Invest Dermatol. 1999 Nov;113(5):808-15. (PMID: 10571738)
Int J Dermatol. 2015 Mar;54(3):258-70. (PMID: 25514833)
Dent Clin North Am. 2013 Oct;57(4):583-96. (PMID: 24034067)
Acta Derm Venereol. 2003;83(1):1-9. (PMID: 12636014)
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 May;103(5):642-54. (PMID: 17344075)
Asia Pac Allergy. 2014 Jan;4(1):54-67. (PMID: 24527412)
Oral Dis. 2005 Sep;11(5):261-7. (PMID: 16120111)
Front Immunol. 2020 Jan 14;10:3100. (PMID: 31993063)
Dermatopathology (Basel). 2019 Jun 26;6(2):111-125. (PMID: 31700852)
Int J STD AIDS. 2009 May;20(5):339-45. (PMID: 19386972)
Oral Dis. 2020 Sep;26 Suppl 1:40-46. (PMID: 32862547)
Am J Emerg Med. 2004 Jul;22(4):330-1. (PMID: 15258890)
Dent Clin North Am. 2005 Jan;49(1):67-76, viii. (PMID: 15567361)
J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):561-6. (PMID: 18645517)
J Emerg Med. 2015 Dec;49(6):e197-8. (PMID: 26281815)
Curr HIV Res. 2004 Jan;2(1):23-37. (PMID: 15053338)
Arch Dermatol. 1995 Nov;131(11):1268-72. (PMID: 7503570)
فهرسة مساهمة: Keywords: Adverse drug reactions; Erythema Multiforme; HAART; HIV; Mucocutaneous lesions; Polypharmacy
تواريخ الأحداث: Date Created: 20240418 Date Completed: 20240422 Latest Revision: 20240709
رمز التحديث: 20240710
مُعرف محوري في PubMed: PMC11027329
DOI: 10.1186/s12981-024-00607-6
PMID: 38637892
قاعدة البيانات: MEDLINE
الوصف
تدمد:1742-6405
DOI:10.1186/s12981-024-00607-6